MedTrace Logo

Effects of a Complete Diet in Critically Ill Patients With Stress Hyperglycemia

NCT01233726 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2016-09-01

Study results available
· View outcomes & findings →

Summary

The aim of the study is to evaluate the beneficial effects of the administration of a complete diet rich in monounsaturated fatty acids (MUFA) and slow absorption carbohydrate in patients with stress hyperglycemia(T-Diet Plus Diabet IR).

The main objective of this project is to evaluate blood glucose metabolic control, insulin requirements, insulin action resistance, lipid profile and to reduce infectious complications on mechanical ventilation ICU (intensive care unit) patients after the administration of a complete diet enriched in MUFA and slow absorption carbohydrates, without fructose.

Conditions

  • Critical Illness
  • Hyperglycemia
  • Dietary Modification
  • Metabolic Stress Hyperglycemia
  • Mechanical Ventilation Complication

Interventions

DIETARY_SUPPLEMENT

T-Diet plus Diabet IR

Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.

DIETARY_SUPPLEMENT

ISOSOURCE PROTEIN FIBRE

Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.

DIETARY_SUPPLEMENT

GLUCERNA SELECT

Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.

Sponsors & Collaborators

  • Vegenat, S.A.

    lead INDUSTRY

Principal Investigators

  • Alfonso Mesejo, PhD · Hospital Clinico Universitario de Valencia

  • Juan Carlos Montejo, PhD · Hospital Universitario 12 de Octubre

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01233726 on ClinicalTrials.gov